BioSpace News Archive

Medicinal Genomics Corp. (MGC), today announced its new PathoSEEK® 5-Color Aspergillus Multiplex Assay that independently identifies four species of pathogenic Aspergillus

Once just a snack, pistachios possess extracts that have been shown to stop the growth of Staphylococcus aureus, MRSA, Listeria and Herpes simplex virus (HSV-1) —important findings amid growing antibiotics resistance and the increased need for new medical treatments.

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present abstracts with new data on berotralstat (BCX7353), an oral, once daily therapy under regulatory review in the United States and Japan for the prevention of hereditary angioedema (HAE) attacks, at the upcoming annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) March 13-16 in Philadelphia.

Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced its financial results and business highlights for the fourth quarter ended December 31, 2019.

Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments, today announced that the Company’s investigational CD30-directed autologous chimeric antigen receptor T cell (CD30 CAR-T) therapy has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory CD30-positive classical Hodgkin lymphoma (cHL).

Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will present at the following upcoming investor conferences

CANTEL MEDICAL CORP. (NYSE: CMD) announced today that in line with its focus on key growth opportunities, Seth Yellin has been promoted to the newly created role of Executive Vice President and Chief Growth Officer

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report fiscal 2019 financial results on Thursday, March 5, 2020 at 4:45PM EST

Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, announced that management will present a company overview at the following investor conferences:

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in the Cowen 40th Annual Healthcare Conference in Boston.